December 1, 2024 - 16:33

As the new administration approaches, industry experts are contemplating significant shifts in the cryptocurrency landscape. Mark Palmer, a Managing Director and Senior Research Analyst, recently shared his insights on potential regulatory changes that could reshape the sector.
Palmer highlighted the pressing need for a more structured approach to cryptocurrency regulation, contrasting it with the current strategy employed by the SEC under Gary Gensler. He criticized what he termed "regulation by enforcement," which has created uncertainty for institutional investors. This lack of a clear regulatory framework has deterred many from engaging with the burgeoning asset class, as they fear sudden interventions from federal regulators could jeopardize their projects.
The hope is that the incoming administration will usher in a more conducive environment for crypto, fostering institutional adoption and innovation. The anticipation surrounding these changes reflects a broader desire within the industry for clarity and stability, which could ultimately lead to a more robust and secure cryptocurrency market.
June 8, 2026 - 22:27
What history tells us about Marvell's upcoming S&P 500 inclusionMarvell Technology shares have been climbing sharply after the announcement that the company will join the S&P 500 index on June 22. Investors are betting that the move will bring fresh demand from...
June 8, 2026 - 04:51
Is PDD Holdings Inc. (PDD) A Good Stock To Buy Now?A recent discussion on a value investing forum laid out a bullish case for PDD Holdings Inc., the parent company of e-commerce platforms Temu and Pinduoduo. As of late May, shares were trading near...
June 7, 2026 - 03:13
Apple Stock: Buy, Sell, or Hold?Apple`s stock is trading close to an all-time high, and a series of potential catalysts could sustain the upward momentum. The company continues to benefit from strong demand for its latest iPhone...
June 6, 2026 - 22:38
Eli Lilly's $3.8 Billion Vaccine Bets: Here's the Big Story Many Investors Are MissingEli Lilly is making a serious push into the vaccine business. The pharmaceutical giant announced a trio of acquisitions totaling $3.8 billion, aimed at building a new division focused on infectious...